| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| TNA-H5228 | Human | Human TNF-alpha Protein, His Tag |  |
|
|
| TNA-M82E9 | Mouse | Biotinylated Mouse TNF-alpha (HPLC-verified), Avi Tag (Avitag™) |  |
|
|
| TNA-H82E3 | Human | Biotinylated Human TNF-alpha (HPLC-verified), Avi Tag (Avitag™) |  |
|
|
| TNA-H8211 | Human | Biotinylated Human TNF-alpha, epitope tag free, ultra sensitivity (primary amine labeling) |  |
|
|
| TNA-H4211 | Human | ActiveMax® Recombinant Human TNF-alpha (HPLC-verified), low endotoxin |  |
|
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Etanercept biosimilar (Hanwha Chemical) | HD-203; MK-8953 | Approved | Hanwha Chemical | Ankylosing Spondylitis (AS), Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |||||
| Etanercept-szzs | GP-2015 | Approved | Sandoz | ERELZI | fda | Ankylosing Spondylitis (AS), Juvenile idiopathic arthritis (JIA), Psoriatic arthritis, Rheumatoid arthritis (RA), Plaque psoriasis | SANDOZ | 2016-08-30 | Juvenile idiopathic arthritis (JIA), Spondyloarthritis, Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details |
| Infliximab | TA-650 | Approved | Janssen, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma | infliximab | ema | Janssen Biologics B.V. | 1999-08-13 | Pediatric ulcerative colitis, Psoriasis vulgaris, Crohn's disease, Mucocutaneous lymph node syndrome (Kawasaki syndrome), Psoriatic erythroderma, Ankylosing Spondylitis (AS), Uveitis, Pustular psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Behcet's disease, Pediatric Crohn's disease | Details | |
| Etanercept biosimilar (AryoGen Biopharma) | Approved | AryoGen Biopharma | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | ||||||
| Certolizumab pegol | CZP; CDP-870; PHA-738144,CDP870,PHA738144 | Approved | UCB | Certolizumab pegol | 日本 | Rheumatoid arthritis (RA) | 优时比 | 2012-12-25 00:00:00.0 | Plaque psoriasis, Spondyloarthritis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | Details |
| Etanercept biosimilar (PROBIOMED) | Approved | Probiomed | Rheumatoid arthritis (RA) | Details | ||||||
| Etanercept | TNR-001; NK-001,TNR001; NK001 | Approved | Amgen, Pfizer, Takeda, Boehringer Ingelheim | ENBREL | fda | Pediatric plaque psoriasis, Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | IMMUNEX | 1998-11-02 | Juvenile idiopathic arthritis (JIA), Spondyloarthritis, Plaque psoriasis, Pediatric plaque psoriasis, Ankylosing Spondylitis (AS), Psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details |
| Adalimumab biosimilar (Zydus Cadila) | Approved | Zydus cadila | Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | ||||||
| Etanercept biosimilar (Shanghai CP Guojian Pharmaceutical) | Approved | Shanghai CP Guojian, Cipla | cfda | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA), Plaque psoriasis | 2015-01-27 | Plaque psoriasis, Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |||
| Etanercept biosimilar (Samsung Bioepis) | SB-4 | Approved | Samsung Bioepis | etanercept | ema | Samsung Bioepis UK Limited5th FloorProfile West950 Great West RoadBrentfordTW8 9ESUnited Kingdom | 2016-01-14 | Juvenile idiopathic arthritis (JIA), Spondyloarthritis, Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Fujifilm Kyowa Kirin Biologics) | FKB-327,FKB327; FKB 327 | Approved | Fujifilm group | Plaque psoriasis, Uveitis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriasis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | |||||
| Adalimumab biosimilar (Mylan) | BMO-2; MYL-1401-A | Approved | Biocon, Mylan | adalimumab | ema | Mylan S.A.S. | 2018-09-17 | Uveitis, Spondyloarthritis, Psoriasis, Ulcerative colitis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Sandoz) | GP-2017 | Approved | Sandoz | adalimumab | ema | Sandoz GmbH | 2018-07-26 | Juvenile idiopathic arthritis (JIA), Uveitis, Spondyloarthritis, Pediatric plaque psoriasis, Ulcerative colitis, Psoriasis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease | Details | |
| Infliximab biosimilar (Bionovis/The Instituto Vital Brazil) | Approved | Bionovis, The Instituto Vital Brazil | Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | Details | ||||||
| Etanercept biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | ||||||
| Etanercept biosimilar (Mochida) | Approved | Mochida, Ayumi | 日本 | Rheumatoid arthritis (RA), Juvenile idiopathic arthritis (JIA) | 持田制药 | 2018-01-19 00:00:00.0 | Juvenile idiopathic arthritis (JIA), Rheumatoid arthritis (RA) | Details | ||
| Adalimumab-adbm | BI-695501 | Approved | Boehringer Ingelheim | CYLTEZO | fda | Juvenile idiopathic arthritis (JIA), Ankylosing Spondylitis (AS), Plaque psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | BOEHRINGER INGELHEIM | 2017-08-25 | Juvenile idiopathic arthritis (JIA), Uveitis, Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | Details |
| Golimumab | CNTO-148; rTNV148B,CNTO148 | Approved | Janssen, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma | SIMPONI | fda | Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA) | CENTOCOR ORTHO BIOTECH INC | 2009-04-24 | Juvenile idiopathic arthritis (JIA), Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA) | Details |
| Infliximab-ABDA | SB-2 | Approved | Samsung Bioepis, Merck Sharp & Dohme | infliximab | ema | Samsung Bioepis UK Limited (SBUK) | 2016-05-26 | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease, Pediatric Crohn's disease | Details | |
| Infliximab-qbtx | PF-06438179; PF-6438179; GP-1111,PF06438179; PF6438179 | Approved | Pfizer, Sandoz | IXIFI | fda | PFIZER INC | 2017-12-13 | Psoriatic erythroderma, Ankylosing Spondylitis (AS), Plaque psoriasis, Pustular psoriasis, Ulcerative colitis, Psoriatic arthritis, Psoriasis vulgaris, Crohn's disease, Rheumatoid arthritis (RA), Pediatric Crohn's disease | Details | |
| Pentoxifylline; Oxpentifylline | BL-191; EHT-0201; EHT-201 | Approved | Us Pharm Holdings | TRENTAL | fda | US PHARM HOLDINGS | 1984-08-30 | Peripheral vascular disorders | Details | |
| Infliximab-dyyb | CT-P13,CTP13 | Approved | Celltrion, Hospira, Nippon Kayaku | infliximab | ema | Pfizer Europe MA EEIG | 2013-09-10 | Psoriatic erythroderma, Plaque psoriasis, Ankylosing Spondylitis (AS), Pustular psoriasis, Psoriasis, Ulcerative colitis, Psoriatic arthritis, Psoriasis vulgaris, Crohn's disease, Rheumatoid arthritis (RA), Pediatric Crohn's disease | Details | |
| Etanercept biosimilar (Hisun-Pfizer Pharmaceuticals) | Approved | Hisun-Pfizer | Rheumatoid arthritis (RA) | Details | ||||||
| Infliximab biosimilar (Nichiiko Pharmaceutical/Aprogen) | GS-071; NI-071,GS071; NI071 | Approved | Nichi-Iko Pharmaceutical, Aprogen, Zeria, Ayumi | Infliximab biosimilar (Nichiiko Pharmaceutical/Aprogen) | 日本 | Rheumatoid arthritis (RA), Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Crohn's disease, Ulcerative colitis | Nichi-Iko Pharmaceutical,Zeria | 2017-09-27 00:00:00.0 | Pustular psoriasis, Ulcerative colitis, Psoriatic arthritis, Psoriasis vulgaris, Crohn's disease, Rheumatoid arthritis (RA) | Details |
| Adalimumab-ATTO | ABP-501,ABP501 | Approved | Amgen, Daiichi Sankyo | AMJEVITA | fda | Juvenile idiopathic arthritis (JIA), Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | AMGEN INC | 2016-09-23 | Juvenile idiopathic arthritis (JIA), Uveitis, Ankylosing Spondylitis (AS), Plaque psoriasis, Ulcerative colitis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Samsung Bioepis) | SB-5 | Approved | Samsung Bioepis | adalimumab | ema | Samsung Bioepis UK Limited (SBUK) | 2017-08-24 | Pediatric plaque psoriasis, Spondyloarthritis, Hidradenitis suppurativa, Crohn's disease, Juvenile idiopathic arthritis (JIA), Uveitis, Ankylosing Spondylitis (AS), Psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Pediatric Crohn's disease | Details | |
| Lenalidomide | CDC-501; CC-5013; CDC-5013; ENMD-0997; IMID-5013; IMiD3,CC 5013,CDC 501,CC5013,CDC501,IMiD-1 | Approved | Celgene, BeiGene | REVLIMID | fda | Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM) | CELGENE | 2005-12-27 | Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM), Peripheral T cell lymphoma (PTCL) | Details |
| Adalimumab | D2E7; LU-200134; ABT-D2E7 | Approved | Abbvie | HUMIRA | fda | ABBVIE INC | 2002-12-31 | Spondyloarthritis, Hidradenitis suppurativa, Crohn's disease, Juvenile idiopathic arthritis (JIA), Ankylosing Spondylitis (AS), Plaque psoriasis, Uveitis, Pustular psoriasis, Psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA), Pediatric Crohn's disease | Details | |
| Infliximab biosimilar (Reliance Life Sciences) | BOW-015; R-TPR-015 | Approved | EPIRUS Biopharmaceuticals, Sun Pharmaceutical | Rheumatoid arthritis (RA) | Details | |||||
| Infliximab biosimilar (AXXO) | Approved | AXXO | Autoimmune diseases, Crohn's disease | Details | ||||||
| Etanercept biosimilar (Amega Biotech) | Approved | Amega Biotech | Rheumatoid arthritis (RA) | Details | ||||||
| Etanercept biosimilar (Mycenax Biotech/TSH Biopharm) | E-11; ENIA-11,E11; ENIA11 | Approved | Mycenax Biotech, TSH Biopharm | Rheumatoid arthritis (RA) | Details | |||||
| Adalimumab biosimilar (Reliance Life Sciences) | R-TPR-021 | Approved | Reliance Life Sciences, Torrent Pharmaceuticals | Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |||||
| Thalidomide | NSC-527179,K 17,NSC527179,NSC66847,K-17,NSC-66847,K17,NSC 527179,NSC 66847 | Approved | Celgene | THALOMID | fda | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | CELGENE | 1998-07-16 | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | Details |
| Anti-tumour necrosis factor-alpha antibody | Approved | Materia Medica Holding Research and Production Company | Osteoarthritis (OA), Rheumatoid arthritis (RA) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| tgAAC 94 | Phase Ⅱ | AmpliPhi Biosciences Corporation | Rheumatoid arthritis (RA), Periodontal disease | Details | |
| Infliximab biobetter (Mabtech/Sorrento) | STI-002 | Phase Ⅲ | Taizhou Mabtech, Sorrento Therapeutics | Rheumatoid arthritis (RA) | Details |
| Etanercept biosimilar (Nanogen Biopharmaceutical) | BLA Filing | Nanogen Biopharmaceutical Co | Psoriasis, Rheumatoid arthritis (RA) | Details | |
| Recombinant anti-TNFα monoclonal antibody (Wuhan Institute of Biological Products) | IND Filing | Wuhan Institute of Biological Products | Unspecified | Details | |
| Recombinant anti-TNFα antibody (Shanghai Xiesheng Medicine) | Phase Ⅰ | Shanghai Xiesheng Pharmaceutical Technology | Unspecified | Details | |
| Adalimumab biosimilar (Shanghai Maitaiyabo Biotech) | IND Filing | Shanghai Maitai Yabo Biological Technology | Rheumatoid arthritis (RA) | Details | |
| Hemay007 | Hemay-007,Hemay007 | Phase Ⅰ | Tianjin Hemay Biotech | Rheumatoid arthritis (RA), Inflammatory bowel disease | Details |
| BLX-1002 | BLX-1002 | Phase Ⅱ | Orchid | Type 2 diabetes | Details |
| Adalimumab biosimilar (Bionovis/The Instituto Vital Brazil) | Phase Not Specified | Bionovis, The Instituto Vital Brazil | Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | Details | |
| Infliximab biosimilar (Shanghai CP Guojian Pharmaceutical) | Phase Ⅲ | Shanghai CP Guojian | Rheumatoid arthritis (RA) | Details | |
| HMPL-004 (Hutchison Medipharma) | HMPL-004 | Phase Ⅲ | Hutchison Medipharma | Ulcerative colitis, Crohn's disease | Details |
| Recombinant anti-TNFα antibody (Sailemin Biotech) | IND Filing | Hainan Sailemin Biological Technology | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| LME-636 | ESBA-1622; LME-636 | Phase Ⅱ | Alcon | Uveitis, Dry eye disease | Details |
| REN-1654 | CPI-1189; REN-1189; REN-1654,REN1654,REN1189,CPI1189 | Phase Ⅱ | Evotec | Postherpetic neuralgia (PHN), Sciatica | Details |
| Adalimumab biosimilar (LG Life Sciences) | LBAL | Phase Ⅲ | LG Chem, Mochida | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Beijing Luzhu Biotechnology) | Phase Ⅰ | Beijing Luzhu Biotechnology | Rheumatoid arthritis (RA) | Details | |
| ONO-4007 | ONO-4007 | Phase Ⅱ | Ono Pharmaceutical | Cancer chemotherapy | Details |
| Recombinant human anti-TNFα monoclonal antibody (Taizhou Mabtech) | IND Filing | Taizhou Mabtech | Unspecified | Details | |
| PUR-0110 | PUR-0110; PCT-233 | Phase Ⅱ | PurGenesis Technologies | Ulcerative colitis | Details |
| ISIS-104838 | ISIS 104838 | Phase Ⅱ | Ionis Pharmaceuticals | Psoriasis, Rheumatoid arthritis (RA) | Details |
| CC-10015 | CC-10015 | Phase Ⅰ | Celgene | Systemic sclerosis | Details |
| LP-0058 | LP-0058; LEO-32731,LP0058,LEO32731 | Phase Ⅱ | Leo Pharma | Psoriasis, Atopic dermatitis | Details |
| Adalimumab biosimilar (Oncobiologics) | ONS-3010 | Phase Ⅲ | Oncobiologics | Plaque psoriasis | Details |
| LY-3114062 | LY-3114062,LY3114062 | Phase Ⅰ | Lilly | Arthritis | Details |
| Adalimumab biosimilar (CTTQ Pharma) | Phase Ⅰ | Chiatai Tianqing (CTTQ) | Rheumatoid arthritis (RA) | Details | |
| QR-449 | QR-440; QR-443; QR-449 | Phase Ⅰ | ProPhase Labs | Cachexia, Metabolic disorders, Pain | Details |
| Infliximab biosimilar (Shanghai Biomabs) | BLA Filing | Shanghai Biomabs | Rheumatoid arthritis (RA) | Details | |
| EYS-606 | EYS-606 | Phase Ⅱ | Eyevensys | Uveitis | Details |
| HP-228 | HP-228; ILP-228 | Phase Ⅱ | Sygnis | Obesity, Type 2 diabetes, Postoperative pain, Inflammation | Details |
| Adalimumab biosimilar (Coherus BioSciences) | CHS-1420 | Phase Ⅲ | Coherus Biosciences | Plaque psoriasis | Details |
| Adalimumab biosimilar (CinnaGen) | Phase Ⅲ | CinnaGen | Rheumatoid arthritis (RA) | Details | |
| Infliximab biosimilar (Biocad) | BCD-055 | Phase Ⅲ | Biocad | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details |
| Infliximab biosimilar (Genor Biopharma) | GB-242,GB242 | Phase Ⅲ | Genor Biopharma | Rheumatoid arthritis (RA) | Details |
| CDP-571 | CDP-571; BAY-10-3356; cb-0010,CDP 571; BAY 10 3356; cb 0010,CDP571; BAY103356; cb0010 | Phase Ⅲ | Celltech, Biogen | Type 2 diabetes, Septic shock, Rheumatoid arthritis (RA), Crohn's disease | Details |
| Adalimumab biosimilar (Biocad) | BCD-057 | Phase Ⅲ | Biocad | Plaque psoriasis, Rheumatoid arthritis (RA) | Details |
| Recombinant anti-TNFα monoclonal antibody (Livzon Group) | AT-132 | Phase Ⅱ | Livzon Group Livzon Pharmaceutical Factory | Rheumatoid arthritis (RA) | Details |
| Placulumab | ART-621; CEP-37247; PN-0621; Dom-0200 | Phase Ⅱ | Peptech UK, Domantis, Arana, Teva | Psoriasis, Inflammation, Rheumatoid arthritis (RA), Sciatica | Details |
| Recombinant human TNF-α monoclonal antibody(Sinocelltech) | Phase Ⅰ | Sinocelltech | Rheumatoid arthritis (RA) | Details | |
| AZD-9773 (BTG) | Phase Ⅱ | BTG plc, AstraZeneca | Septic shock, Sepsis | Details | |
| JNJ-63823539 | JNJ-63823539 | Phase Ⅰ | Janssen | Rheumatoid arthritis (RA) | Details |
| Etanercept biosimilar (Bionovis/The Instituto Vital Brazil) | Phase Not Specified | Bionovis, The Instituto Vital Brazil | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Alphamab) | KN-002 | Phase Ⅰ | Alphamab | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Danhong Pharma) | Phase Ⅰ | Danhong Pharma | Plaque psoriasis, Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| NPH-30907 | NPH-30907 | Phase Ⅱ | Piramal Phytocare | Fungal infection | Details |
| Adalimumab biosimilar (Tonghua Dongbao Pharmaceutical) | Phase Ⅰ | Tonghua Dongbao Pharmaceutical | Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Shanghai Henlius Biotech) | HLX-03,HLX03 | Phase Ⅲ | Shanghai Henlius Biotech | Plaque psoriasis, Rheumatoid arthritis (RA) | Details |
| INDUS-83030 | INDUS-83030 | Phase Not Specified | Indus Biotech Private Limited | Rheumatoid arthritis (RA) | Details |
| AMG-548 | AMG-548 | Phase Ⅰ | Amgen | Rheumatoid arthritis (RA), Arthritis | Details |
| Recombinant human anti-TNFα monoclonal antibody (Qilu Pharmaceutical) | IND Filing | Qilu Pharmaceutical | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| Recombinant chimeric anti-TNFα antibody (Hisun Pharma) | HS-626,HS626 | Phase Ⅰ | Hisun Pharm | Rheumatoid arthritis (RA) | Details |
| ABT-122 | ABT-122; D2E7-GS10-B6-17 | Phase Ⅱ | Abbvie | Rheumatic disorders, Psoriatic arthritis | Details |
| Tumour necrosis factor alpha kinoid | TNF-K; TNF-K005 | Phase Ⅱ | Neovacs | Rheumatoid arthritis (RA), Crohn's disease | Details |
| Etanercept biosimilar (Clover Biopharmaceuticals) | SCB-808,SCB808 | Phase Ⅰ | Clover Biopharmaceuticals | Rheumatoid arthritis (RA) | Details |
| IBPM005IX (Inbiopro Solutions) | Phase Not Specified | Inbiopro Solutions | Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease, Juvenile rheumatoid arthritis (JRA) | Details | |
| Etanercept biosimilar (AvesthaGen) | Phase Ⅲ | Avesthagen | Rheumatoid arthritis (RA) | Details | |
| K-832 | K-832 | Phase Ⅱ | Kowa | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Momenta Pharmaceuticals) | BAX-2923; M-923; BAX-923 | Phase Ⅲ | Momenta, Shire | Plaque psoriasis, Autoimmune diseases, Inflammation, Rheumatoid arthritis (RA) | Details |
| CBP-1011 | CBP-1011 | Phase Ⅲ | Salix Pharmaceutical | Idiopathic thrombocytopenic purpura (ITP) | Details |
| ABP-710 | ABP-710 | Phase Ⅲ | Amgen | Rheumatoid arthritis (RA) | Details |
| AN-0128 | AN-0128; CRM-0005; ONT-0001,AN0128,ONT0001,CRM0005,Borinic acid ester - Anacor | Phase Ⅱ | Anacor Pharmaceuticals | Atopic dermatitis | Details |
| V-565 | V-565 | Phase Ⅱ | VHSquared | Crohn's disease | Details |
| Etanercept biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) | BLA Filing | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Rheumatoid arthritis (RA) | Details | |
| Anti-tumour necrosis factor alpha (Livzon) | Phase Ⅰ | Livzon Group | Autoimmune diseases | Details | |
| Recombinant human anti-TNFα monoclonal antibody (Weimingdamu Biotech) | IND Filing | Anhui Sinobioway Damu Biomedicine | Rheumatoid arthritis (RA) | Details | |
| YS-IL6 | YS-IL6; YSIL-6; YSIL6-O-RA; YSIL6-T-PS | Phase Ⅱ | Y's Therapeutics | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Merck Serono) | MSB-11022,MSB11022; MSB 11022 | BLA Filing | Merck Serono, Fresenius Kabi | Autoimmune diseases | Details |
| OCT-B201 | OCT-B201; BT-201 | Phase Ⅰ | Oscotec | Osteoarthritis (OA) | Details |
| Certolizumab (Intrexon) | AG-014 | Phase Ⅰ | Intrexon Corporation | Inflammatory bowel disease | Details |
| DLX-105 | DLX-105; ESBA-105 | Phase Ⅱ | ESBATech, Cell Medica | Uveitis, Plaque psoriasis, Crohn's disease, Dry eye disease | Details |
| Etanercept biosimilar (Biotrion) | BT-D001; BTD-001,BT D001; BTD 001,BTD001 | Phase Ⅲ | Biotrion | Rheumatoid arthritis (RA) | Details |
| Etanercept biosimilar (Shanghai Celgen) | Phase Ⅲ | Shanghai Celgen Bio | Plaque psoriasis | Details | |
| Adalimumab biosimilar (Innovent Biologics) | IBI-303 | BLA Filing | Innovent Biologics | Ankylosing Spondylitis (AS) | Details |
| AVX-470 | AVX-1350; AVX-470; AVX-470h | Phase Ⅰ | Avaxia Biologics | Ulcerative colitis | Details |
| COVA-322 | COVA-322 | Phase Ⅱ | Covagen | Plaque psoriasis | Details |
| CYT 007 TNFQb | Phase Ⅱ | Cytos | Psoriasis, Rheumatoid arthritis (RA) | Details | |
| MNX-160 | LMP-160; MNX-160 | Preclinical | Nonindustrial source, Macronex | Cachexia, Diabetes, Psoriasis, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Asthma, Adult respiratory distress syndrome (ADRS) | Details |
| KOB-03 | KOB-03 | Phase Ⅱ | Dong Wha Pharmaceuticals | Allergic rhinitis (AR) | Details |
| GSK-2800528 | GSK-2800528 | Phase Ⅰ | GlaxoSmithKline | Psoriasis, Inflammation | Details |
| Adalimumab biosimilar (Alvotech) | AVT-02 | Phase Ⅰ | Alvotech | Autoimmune diseases | Details |
| BIRB-1017 | BIRB-1017 | Phase Not Specified | Boehringer Ingelheim | Psoriasis, Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Pfizer) | PF-06410293 | Phase Ⅲ | Pfizer | Ankylosing Spondylitis (AS), Psoriatic arthritis, Psoriasis vulgaris, Crohn's disease, Rheumatoid arthritis (RA), Behcet's disease, Arthritis | Details |
| ENMD-0995 | S-3APG; ENMD-0995 | Phase Ⅰ | Celgene, Boston Children's Hospital | Multiple myeloma (MM) | Details |
| PMI-001 | PMI-001,PMI 001,PMI001 | Phase Ⅲ | Phytomedics | Lupus vulgaris, Psoriasis, Multiple sclerosis (MS), Rheumatoid arthritis (RA) | Details |
| Recombinant anti-TNFα human monoclonal antibody (Jilin Kanghui Biotech) | IND Filing | Jilin Kanghui Biological Technology | Unspecified | Details | |
| Adalimumab biosimilar (Hualan Biological Engineering) | Phase Ⅰ | Hualan Biological Engineering | Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Bio-Thera Solutions) | BAT-1406 | BLA Filing | Bio-Thera Solutions | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details |
| Ozoralizumab | ATN-103; PF-05230896; PF-5230896; TS-152 | Phase Ⅲ | Ablynx, Eddingpharm, Pfizer, Taisho Pharmaceutical | Rheumatoid arthritis (RA) | Details |
| PF-5230905 | PF-5230905; ATN-192 | Phase Ⅰ | Ablynx | Rheumatoid arthritis (RA) | Details |
| Human anti-TNFα monoclonal antibody (DZM Biotech) | Phase Ⅰ | DZM Biotech | Rheumatoid arthritis (RA) | Details | |
| YHB-1411-2 | YHB-1411-2; YHB1411-2; YHB-14112; MAb YHB1411-2 | Phase Ⅰ | Yuhan Corporation | Rheumatoid arthritis (RA) | Details |
| Recombinant human monoclonal antibody specific for human tumor necrosis factor (North China Pharmaceutical) | Phase Ⅰ | North China Pharmaceutical | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| ABBV-257 | ABBV-257; DVD-1; DVD-Ig-1 | Phase Ⅰ | Abbott | Rheumatoid arthritis (RA) | Details |
| NV-52 | NV-52; NV-07; NV-07b; NV-07beta | Phase Ⅱ | Novogen | Ulcerative colitis, Crohn's disease, Inflammatory bowel disease | Details |
| Lenercept (Roche) | RO-452081 | Phase Ⅲ | Roche | Septic shock, Rheumatoid arthritis (RA) | Details |
| HL-036 | HL-036; HBM-9036,HL036; HL 036; HBM9036, HL-036337 | Phase Ⅱ | HanAll, Harbour BioMed, Daewoong | Dry eye disease | Details |
| UBP1211 | UBP-1211,UBP1211; UBP 1211 | Phase Ⅲ | Jiangsu Zhonghe Medicine, Shanghai Junshi Biosciences | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Celltrion) | CT-P17 | IND Filing | Celltrion | Rheumatoid arthritis (RA) | Details |
| Anti-TNFalpha polyclonal antibody (Verigen) | Phase Ⅱ | Genzyme, Italchimici | Crohn's disease, Rheumatoid arthritis (RA) | Details | |
| Etanercept biosimilar (Coherus Biosciences) | BAX-2200; CHS-0214 | Phase Ⅲ | Coherus Biosciences, Daiichi Sankyo | Plaque psoriasis, Rheumatoid arthritis (RA) | Details |
| Recombinant human anti-TNFα antibody (Hisun Pharma) | HS-016 | BLA Filing | Hisun Pharm | Ankylosing Spondylitis (AS) | Details |
| SA-13353 | DE-096; SA-13353,DE096,SA13353 | Phase Ⅱ | Santen, Ayumi | Rheumatoid arthritis (RA), Diabetic macular edema | Details |
| Prasterone Sulfate | PB-005; DHEAS | Phase Ⅱ | Inflabloc, Jenapharm | Burns, Asthma | Details |
| Adalimumab biosimilar (Dong-A ST/Meiji Seika Pharma) | DA-3113; DMB-3113 | Phase Ⅰ | Dong-A Pharmaceutical, Meiji Seika Pharma | Rheumatoid arthritis (RA) | Details |
| Ro-327315 | Ro-327315; Ro-32-7315 | Phase Ⅰ | Roche | Rheumatoid arthritis (RA) | Details |
| Etanercept biosimilar (YL Biologics) | YLB-113 | BLA Filing | Lupin, YL Biologics | Rheumatoid arthritis (RA) | Details |
| Recombinant humanized anti-TNFα monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | IND Filing | Shenzhen Main Luck Pharmaceuticals | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Hetero Drugs) | Phase Ⅲ | Hetero Drugs | Rheumatoid arthritis (RA) | Details | |
| BB-2275 | BB-2275 | Preclinical | Vernalis | Cachexia, AIDS related cachexia, Cancer related cachexia | Details |
| Infliximab biosimilar (Shanghai biomabs) | CMAB-008 | Phase Ⅲ | Shanghai Biomabs, SinoMab Bioscience Ltd | Rheumatoid arthritis (RA) | Details |
| Genz-29155 | Genz-29155 | Phase Ⅰ | Sanofi | Transplant rejection, Multiple sclerosis (MS) | Details |
| Doramapimod | BIBR-796; BIRB-0796; BIRB-796; BIRB-796-BS,BIBR796,BIRB0796,BIRB796 BS | Phase Ⅲ | Boehringer Ingelheim | Psoriasis | Details |
| Adalimumab biosimilar (Synermore Biologics) | SYN-060,SYN060; SYN 060 | Phase Ⅰ | Synermore Biologics, Lonn Ryonn Pharma | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Eastern Biotech) | JY-026,JY026 | Phase Ⅰ | Eastern Biotech | Juvenile idiopathic arthritis (JIA), Plaque psoriasis, Ankylosing Spondylitis (AS), Crohn's disease, Rheumatoid arthritis (RA) | Details |
| BCD-121 | BCD-121 | Phase Ⅰ | Biocad | Rheumatoid arthritis (RA) | Details |
| Golnerminogene pradenovec | ADgvEGR.TNF.11D | Phase Ⅲ | Asahi Kasei, GenVec, National Cancer Institute | Pancreatic cancer | Details |
| Acetylcysteine/Pentoxifylline; Oxpentifylline | PTL-202 | Phase Ⅰ | Pacific Therapeutics, IntelGenx Corp, RA Chem Pharma | Idiopathic pulmonary fibrosis (IPF) | Details |
| Wogonin | Phase Ⅰ | Daewoong, China Pharmaceutical University, Hefei Cosource Medicine Technology | Gastric cancer, Leukemia, Liver cancer | Details |
This web search service is supported by Google Inc.
A-Z
